The global pipeline for antibiotics is rapidly depleting, largely due to market failure as manufacturers lack adequate incentives to produce at a price acceptable to the market. Policy makers worldwide are actively exploring strategies to incentivise manufacturers to engage in research and development of novel antibiotics.
In response, a collaboration involving the Saw Swee Hock School of Public Health (SSHSPH) at the National University of Singapore, Research For Impact (RFI) Singapore, and the Office of Health Economics (OHE) in London, United Kingdom has emerged. Together, the team has released a thought-provoking white paper that delves deep into the question: “What role can Singapore play?” when it comes to pioneering sustainable financing solutions for antibiotics. Curious to explore the nuances of sustainable financing for antibiotics?
Click to dive into the full report:
This project was made possible through funding support from GlaxoSmithKline Pte Ltd, Pfizer Private Limited, MSD International GmBH (Singapore Branch), and MSD Pharma (Singapore) Pte. Ltd. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the report; and decision to disseminate the report.
For information and clarifications, please email: hiper@nus.edu.sg